Trials / Completed
CompletedNCT03305913
Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy
Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy: A Multicenter Phase I Study
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- AIO-Studien-gGmbH · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
0116-ASG REMETY is a multicenter, open-label, non-randomized, dose-escalation Phase I study evaluating the safety and anti-tumor activity of TAS-102 administered in combination with Regorafenib in patients with metastatic colorectal cancer.
Detailed description
The primary objective is to determine safety, feasibility and the recommended phase II dose (RP2D) of a combination treatment consisting of TAS-102 and Regorafenib in subjects with mCRC who have progressed after standard therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAS 102 | TAS-102 tablet |
| DRUG | Regorafenib | Regorafenib tablet |
Timeline
- Start date
- 2017-07-31
- Primary completion
- 2018-10-31
- Completion
- 2019-04-26
- First posted
- 2017-10-10
- Last updated
- 2021-03-26
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03305913. Inclusion in this directory is not an endorsement.